Meeting
2021 ASCO Annual Meeting
A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.
Authors
Martin Gutierrez
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ
Martin Gutierrez , Filip Janku , Linjie Tian , Jason J. Luke , Elaine Shum , John Shin , Ido Weiss , Linda N. Liu , Dallas Files , Solomon Langermann , Han Myint , Marijo Bilusic
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Antibodies
Clinical Trial Registration Number
04408599
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr TPS2659)
DOI
10.1200/JCO.2021.39.15_suppl.TPS2659
Abstract #
TPS2659
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase Ib, open-label, dose-escalation trial of naptumomab estafenatox (Nap) in combination with durvalumab (MEDI4736) in subjects with selected advanced or metastatic solid tumors.
First Author: Ravit Geva
Poster
2022 ASCO Annual Meeting
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 2 open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors.
First Author: Robin Kate Kelley
Poster
2021 ASCO Annual Meeting
Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.
First Author: Vivek Subbiah